Given that data regarding SPECT/CT-based treatment response monitoring are scarce and heterogeneous, the primary goal of this study was to assess the value of quantitative whole-body tumor volumetry performed on SPECT/CT imaging at 48 h after administration of [177Lu]Lu-PSMA I&T therapy in mCRPC patients. The gene discussed is FOLH1; the disease is neoplasm.